| answer text |
<p>The following table shows hospital admission data due to diabetes mellitus and
obesity and other hyperalimentation episodes:</p><table><tbody><tr><td><p> </p></td><td
colspan="2"><p>Admissions</p></td></tr><tr><td><p>Year</p></td><td><p>Diabetes Mellitus</p></td><td><p>Obesity
and other hyperalimentation</p></td></tr><tr><td><p>2019-20</p></td><td><p>59,828</p></td><td><p>11,025</p></td></tr><tr><td><p>2020-21</p></td><td><p>54,811</p></td><td><p>4,095</p></td></tr><tr><td><p>2021-22</p></td><td><p>61,663</p></td><td><p>7,935</p></td></tr><tr><td><p>2022-23</p></td><td><p>61,796</p></td><td><p>8,970</p></td></tr></tbody></table><p>Source:
Hospital Admitted Patient Care Activity, NHS Digital</p><p>The NHS Diabetes Prevention
Programme supports those identified at high risk of type 2 diabetes to reduce their
risk. Latest figures in February 2023 shows a 20% reduction in risk for those who
are referred to the programme compared to those who are not.</p><p>The weight loss
drug Semaglutide (Wegovy) was launched in the United Kingdom on 4 September 2023 and
will be made available on the National Health Service in line with National Institute
for Health and Care Excellence recommendations to ensure cost effective use. A two-year
pilot backed by up to £40 million is being developed to explore ways to make these
drugs accessible to patients living with obesity outside of hospital settings.</p>
|
|
